Skip to main content
Erschienen in: Clinical Research in Cardiology 11/2012

01.11.2012 | Original Paper

Assessment of an asymmetrical coating stent with sirolimus released from ablumial matrix in porcine model

verfasst von: Li Shen, Yizhe Wu, Feng Zhang, Lingxiang Wu, Chao Dong, Yongxing Gao, Aijun Sun, Yunzeng Zou, Juying Qian, Jianguo Sun, Wei Zhong, Junbo Ge

Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Delayed endothelialization contributes to stent thrombosis of current drug-eluting stents. The asymmetrical coating technique provides an anti-proliferative effect abluminally without affecting luminal endothelialization. Layer-by-layer self-assembled chitosan/heparin (C/H LBL) has been proved to promote re-endothelialization. A novel stent system, C/H LBL coated luminally and sirolimus released abluminally (C/H LBL-SES), was fabricated.

Methods

Bare metal stents (BMS), traditionally circumferential sirolimus-eluting stents (SES), and C/H LBL-SES were implanted into porcine coronary arteries. At the 7, 14 and 28 days follow-up (FU), angiography, intravascular ultrasound (IVUS), vasomotor function induced by acetylcholine (Ach), scanning-electron microscopy and histopathology were performed. Remodeling index (RI) was based on IVUS and defined as cross-sectional area (CSA) of vessel at in-stent segment divided by CSA of reference vessel and expressed as a percentage with a normal range from 0.95 to 1.05.

Results

Thirty-eight mini pigs were enrolled and 74 stents (BMS = 23, C/H LBL = 28, SES = 23) were implanted in this study. At 28 days after implantation, the diameter stenosis of C/H LBL-SES by quantitative coronary angiography was 18.8 ± 2.5 %, the area stenosis by histomorphometry was 24.2 ± 2.9 %, which were comparable to that of SES and superior to BMS. At 14 days, re-endothelialization of C/H LBL-SES was almost completed, while only about 50 % of surface of SES was covered by endothelium. At 7, 14 and 28 days FU, although C/H LBL-SES suffered a greater vasoconstriction induced by Ach infusion than BMS (P < 0.05), it behaved better than SES (P < 0.01). No sign of stent malapposition was detected, while RI was within the normal range by IVUS. No acute or subacute thrombotic events occurred in all three groups.

Conclusions

The asymmetrically designed C/H LBL-SES successfully inhibited neointima hyperplasia, while diminishing vasoconstriction after Ach-stress. Endothelialization of C/H LBL-SES was less affected compared with traditionally circumferentially coated SES.
Literatur
1.
Zurück zum Zitat Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323PubMedCrossRef Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323PubMedCrossRef
2.
Zurück zum Zitat Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K (2011) Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol 100:191–200PubMedCrossRef Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K (2011) Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol 100:191–200PubMedCrossRef
3.
Zurück zum Zitat Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, ENDEAVOR III Investigators (2007) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48:2440–2447CrossRef Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, ENDEAVOR III Investigators (2007) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48:2440–2447CrossRef
4.
Zurück zum Zitat Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2:286–294PubMed Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2:286–294PubMed
5.
Zurück zum Zitat de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schömig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol (Epub ahead of print) de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schömig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol (Epub ahead of print)
6.
Zurück zum Zitat Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202PubMedCrossRef Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202PubMedCrossRef
7.
Zurück zum Zitat Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120:141–149PubMedCrossRef Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120:141–149PubMedCrossRef
8.
Zurück zum Zitat Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333–342PubMedCrossRef Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333–342PubMedCrossRef
9.
Zurück zum Zitat Webster MW, Ormiston JA (2007) Drug-eluting stents and late stent thrombosis. Lancet 370:914–915PubMedCrossRef Webster MW, Ormiston JA (2007) Drug-eluting stents and late stent thrombosis. Lancet 370:914–915PubMedCrossRef
10.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef
11.
Zurück zum Zitat Guagliumi G, Sirbu V, Musumeci G, Bezerra HG, Aprile A, Kyono H, Fiocca L, Matiashvili A, Lortkipanidze N, Vassileva A, Popma JJ, Allocco DJ, Dawkins KD, Valsecchi O, Costa MA (2010) Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: optical coherence tomography drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv 3:367–375PubMedCrossRef Guagliumi G, Sirbu V, Musumeci G, Bezerra HG, Aprile A, Kyono H, Fiocca L, Matiashvili A, Lortkipanidze N, Vassileva A, Popma JJ, Allocco DJ, Dawkins KD, Valsecchi O, Costa MA (2010) Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: optical coherence tomography drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv 3:367–375PubMedCrossRef
12.
Zurück zum Zitat Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, Dawkins KD (2010) A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv 3:431–438PubMedCrossRef Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, Dawkins KD (2010) A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv 3:431–438PubMedCrossRef
13.
Zurück zum Zitat Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, Parker S, Rowland SM, Kolodgie FD, Leon MB, Virmani R (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68–75PubMedCrossRef Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, Parker S, Rowland SM, Kolodgie FD, Leon MB, Virmani R (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68–75PubMedCrossRef
14.
Zurück zum Zitat Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R (2010) Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 3:257–266PubMedCrossRef Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R (2010) Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 3:257–266PubMedCrossRef
15.
Zurück zum Zitat Meng S, Liu ZJ, Shen L, Guo Z, Chou LL, Zhong W, Du QG, Ge JB (2009) The effect of a layer-by-layer chitosan–heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 30:2276–2283PubMedCrossRef Meng S, Liu ZJ, Shen L, Guo Z, Chou LL, Zhong W, Du QG, Ge JB (2009) The effect of a layer-by-layer chitosan–heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 30:2276–2283PubMedCrossRef
16.
Zurück zum Zitat Brott BC, Anayiotos AS, Charpman GD, Anderson PG, Hillegass WB (2006) Severe, diffuse coronary artery spasm after drug-eluting stent placement. J Invasive Cardiol 18:584–592PubMed Brott BC, Anayiotos AS, Charpman GD, Anderson PG, Hillegass WB (2006) Severe, diffuse coronary artery spasm after drug-eluting stent placement. J Invasive Cardiol 18:584–592PubMed
17.
Zurück zum Zitat Li J, Jabara R, Pendyala L, Otsuka Y, Shinke T, Hou D, Robinson K, Chronos N (2008) Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv 1:279–285PubMedCrossRef Li J, Jabara R, Pendyala L, Otsuka Y, Shinke T, Hou D, Robinson K, Chronos N (2008) Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv 1:279–285PubMedCrossRef
18.
Zurück zum Zitat Fukuda D, Sata M, Tanaka K, Nagri R (2005) Potent inhibitory effect of the sirolimus on the circulating vascular progenitor cells. Circulation 111:926–931PubMedCrossRef Fukuda D, Sata M, Tanaka K, Nagri R (2005) Potent inhibitory effect of the sirolimus on the circulating vascular progenitor cells. Circulation 111:926–931PubMedCrossRef
19.
Zurück zum Zitat Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844PubMedCrossRef Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844PubMedCrossRef
20.
Zurück zum Zitat Jeanmart H, Malo O, Carrier M, Nickner C, Desjardines N (2002) Comparative study of cyclosporine vs newer immunosuppressants mycophenalate mofetil and rapamycin on the coronary endothelial function. J Heart Lung Transplant 21:990–998PubMedCrossRef Jeanmart H, Malo O, Carrier M, Nickner C, Desjardines N (2002) Comparative study of cyclosporine vs newer immunosuppressants mycophenalate mofetil and rapamycin on the coronary endothelial function. J Heart Lung Transplant 21:990–998PubMedCrossRef
21.
Zurück zum Zitat Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ (2005) Late incomplete apposition after sirolimus-eluting stent implantation. A serial intravascular ultrasound analysis. J Am Coll Cardiol 46:1002–1005PubMedCrossRef Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ (2005) Late incomplete apposition after sirolimus-eluting stent implantation. A serial intravascular ultrasound analysis. J Am Coll Cardiol 46:1002–1005PubMedCrossRef
22.
Zurück zum Zitat van der Hoeven BL, Liem SS, Dijkstra J, Bergheanu SC, Putter H, Antoni ML, Atsma DE, Bootsma M, Zeppenfeld K, Jukema JW, Schalij MJ (2008) Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 1:192–201PubMedCrossRef van der Hoeven BL, Liem SS, Dijkstra J, Bergheanu SC, Putter H, Antoni ML, Atsma DE, Bootsma M, Zeppenfeld K, Jukema JW, Schalij MJ (2008) Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 1:192–201PubMedCrossRef
23.
Zurück zum Zitat Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, Sousa AG, Sousa JE (2007) Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 28:1304–1309PubMedCrossRef Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, Sousa AG, Sousa JE (2007) Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 28:1304–1309PubMedCrossRef
24.
Zurück zum Zitat Lang NN, Newby DE (2007) Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol 27:261–262PubMedCrossRef Lang NN, Newby DE (2007) Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol 27:261–262PubMedCrossRef
Metadaten
Titel
Assessment of an asymmetrical coating stent with sirolimus released from ablumial matrix in porcine model
verfasst von
Li Shen
Yizhe Wu
Feng Zhang
Lingxiang Wu
Chao Dong
Yongxing Gao
Aijun Sun
Yunzeng Zou
Juying Qian
Jianguo Sun
Wei Zhong
Junbo Ge
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 11/2012
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-012-0476-7

Weitere Artikel der Ausgabe 11/2012

Clinical Research in Cardiology 11/2012 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.